Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by EAM Investors LLC

EAM Investors LLC cut its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 23.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,956 shares of the company's stock after selling 22,465 shares during the quarter. EAM Investors LLC owned approximately 0.15% of Mirum Pharmaceuticals worth $3,017,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its position in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the period. R Squared Ltd bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $69,000. AlphaQuest LLC increased its holdings in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after buying an additional 1,658 shares during the period. Summit Investment Advisors Inc. raised its stake in Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after buying an additional 312 shares in the last quarter. Finally, Avanza Fonder AB bought a new position in Mirum Pharmaceuticals in the fourth quarter worth approximately $189,000.

Analysts Set New Price Targets

Several analysts have issued reports on the company. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $58.20.

Insider Activity

In related news, SVP Jolanda Howe sold 57,606 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. This trade represents a 92.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Peetz sold 6,837 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $327,629.04. Following the transaction, the chief executive officer now owns 125,022 shares of the company's stock, valued at $5,991,054.24. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,473 shares of company stock valued at $5,249,134. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Stock Up 1.4 %

Shares of MIRM traded up $0.55 during mid-day trading on Tuesday, hitting $38.94. 105,634 shares of the company traded hands, compared to its average volume of 521,265. The business has a 50 day moving average of $44.98 and a 200 day moving average of $44.01. The company has a market capitalization of $1.93 billion, a PE ratio of -19.24 and a beta of 1.00. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.